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Abstract
Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal
cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic
cytokines. In this study, forty patients in the chronic phase of disease, treated with imatinib mesylate, were analyzed. Bone
marrow aspirates were drawn at diagnosis, after 3, 6, 12, 18 months for haematological, cytofluorimetric, cytogenetic,
biomolecular evaluation and cytokine measurement. Responder and non responder patients were defined according to the
European LeukemiaNet recommendations. In responder patients (n=32), the percentage of bone marrow CD20
+CD5
+sIgM
+
lymphocytes, and the plasma levels of IgM, were significantly higher, at 3 months and up to 9 months, than in non
responders. These IgM reacted with O-linked sugars expressed by leukemic cells and could induce tumor cell apoptosis. In
responeı `der patients the stromal-derived factor-1 and the B-lymphocyte-activating factor of the tumor necrosis factor family
significantly raised in the bone marrow after imatinib administration, together with the bone morphogenetic proteins-2 and
27. All patients with high number of CD20
+CD5
+sIgM
+ cells and high stromal-derived factor-1 and B lymphocyte activating
factor levels, underwent complete cytogenetic and/or molecular remission by 12 months. We propose that
CD20
+CD5
+sIgM
+ lymphocytes producing anti-carbohydrate antibodies with anti-tumor activity, might contribute to the
response to imatinib treatment. As in multivariate analysis bone marrow CD20
+CD5
+sIgM
+ cells and stromal-derived factor-1
and B-lymphocyte-activating factor levels were significantly related to cytogenetical and molecular changes, they might
contribute to the definition of the pharmacological response.
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Introduction
In the last years, tyrosine kinases have become the major targets
of anti-cancer drugs. In particular, imatinib mesylate, an ATP
competitive inhibitor of the constitutively activated ABL1 tyrosine
kinase of the BCR-ABL oncoprotein, resulting from the t(9,22)
reciprocal chromosomal translocation (Ph
+), has become a first line
treatment of Ph
+ Chronic Myelogenous Leukemia (CML) [1,2].
Due to its additional capacity to bind to the KIT and PDGFR-
associated kinases, imatinib also provide an effective treatment of a
rare form of gastrointestinal stromal cancer [3]. In the latter case,
the response to the drug in vivo is thought to be also due to an
effect on immunocompetent cells, able to produce cytokines with
antineoplastic activity, including interferon gamma or type I
interferons [3–5]. In addition, imatinib has been shown to
modulate cytokine expression in human cancer-associated stromal
fibroblasts, enhancing mainly interleukin (IL)-6 and the chemokine
IL-8 [6]. In turn, IL-6 is known to increase the number of bone
marrow (BM) immunoglobulin (Ig)M-secreting B cell, still not
terminally differentiated [7]. Also, it has been reported that BCR-
ABL translocation, beside determining the constitutive activation
of the ABL1 kinase, inhibits the interaction between the stromal-
derived factor (SDF)-1 and its receptor [8,9]. On the other hand,
defective or altered production of SDF-1, have been related to
impaired B cell maturation and differentiation [9,10].
In some patients, resistance to imatinib can occur, or develop
during treatment. This is usually due to point mutations in the
BCR-ABL ATP-binding site, that impede the binding of imatinib
[11]. However, other mechanisms of resistance have been
reported, such as BCR-ABL gene amplification, aberrations in
other oncogenetic signalling pathways, and the persistence of
leukemic stem cells [12–14]. Extrinsic factors contributing to
resistance have also been hypothesized, including multidrug
resistance and microenvironmental factors [14,15].
In this study, we show that the clinical response to imatinib
relates to a significant number in the percentage of BM CD20
+
lymphocytes, co-expressing CD5 and surface (s) IgM. This
phenotype correspond to that of the so called B1 lymphocytes,
producing natural antibodies [16,17]. These antibodies are
increased in the BM of patients responding to the therapy, react
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induce apoptosis. In all responder patients SDF-1 and the B
lymphocyte activating factor of the tumor necrosis factor family
(BAFF) transiently increased in the BM plasma after imatinib
administration. The enhanced production of SDF-1 and BAFF,
partially coexisting with the production of the bone morphogenetic
proteins (BMP)2 and BMP7, that follows imatinib administration
might contribute to the observed raise in BM CD20
+CD5
+sIgM
+
lymphocytes. As all these changes were not detected in patients
resistant to imatinib, they might be proposed as early markers of
the pharmacological response.
Methods
Ethic Committee Approval
This work has been performed in the context of the approved
following Ethic Statements: EUDRACT 2007-005102-42 and
EUDRACT 2008-004384-19; the ethic approval for our study was
obtained from the ethic committee of San Martino Hospital where
the biological samples of participants were taken. According to
these Ethic Statements, from all participants involved in this study
a written informed consent was obtained.
Patients
Forty CML patients, all in the chronic phase of the disease, that
underwent imatinib mesylate treatment (Gleevec; formerly known
as STI571, Novartis Pharma, VA, Italy; 400 mg/daily), were
studied at the Clinical Hematology Division (Department of
Haematology and Oncology, University of Genoa). BM aspirates
were drawn at diagnosis, after 3, 6, 12, 18 months, according to
conventional diagnostic and monitoring procedures, upon in-
formed consent and IRB approval, for haematological, cytogenetic
and biomolecular evaluation (Table 1). BM samples from 10
healthy bone marrow donors were used for comparison. At each
time point, fractions of the samples were frozen for further
experiments. Samples of peripheral blood (PB) were collected as
well. Plasma from BM and PB was also recovered for evaluation of
cytokines. Responder (R, n=32) patients were defined as patients
that obtained either optimal (n=18) or suboptimal response
(n=14) at any time; non responders (NR, n=8) as patients where
imatinib treatment failed by six months, according to the
European LeukemiaNet recommendations [18]. Experiments
were performed on fresh specimens, data collected and stored,
and interpreted retrospectively once the R vs. NR status of the
patients could be assessed.
Immunoflurescence and cytofluorimetry
Samples from BM and PB were subjected to density gradient
centrifugation and purified cells were stained with the fluorescein
isothiocyanate (FITC)-conjugated anti-human sIgM or anti-
human IgG antibody (Sigma Chemical Co., St. Louis, MO),
followed by the allophycocyanin-conjugated (APC)-conjugated
anti-CD20 monoclonal antibody (mAb), the phycoerythrin (PE)-
conjugated anti-CD5 mAb, purchased from BD Pharmingen
Europe (Milan, Italy). Control samples were stained with APC-,
FITC- or PE-conjugated irrelevant mAbs (BD Pharmingen). In
other experiments, BM plasma samples obtained from CML
patients, diluted 1:2, 1:10, 1:80, were incubated with autologous or
allogeneic leukemic cells, isolated from BM samples drawn at the
onset of the disease (at that time leukemic cells in the BM were
always .90%), purified by negative depletion of monocytes and of
T or B lymphocytes performed using the appropriate kit of the
StemCell Technology (Vancouver, Canada) and kept frozen until
use. Then FITC-anti-human sIgM or anti-human IgG antibody
was then added. Some samples of CML were treated with 20 mU/
mL O-glycosidase (Boehringer, Mannheim, Germany) or 10 mU/
mL N-glycosidase (Roche Diagnostic GmbH, Mannheim, Ger-
many) for 4 h at 37uC before incubation with BM plasma. After
washing, samples were run on a CyAn ADP cytofluorimeter
(Beckman-Coulter), gated either on lymphocytes or on leukemic
cells, after exclusion of cell debris on the basis of FSC and SSC,
and results expressed as percentage of positive cells or as arbitrary
units of mean fluorescence intensity (MFI a.u.)
Apoptosis assay
For apoptosis vs. cytotoxicity evaluation, CML cells obtained at
diagnosis as described, were incubated with autologous or
allogenic BM plasma (in some experiments plasma samples
incubated 30 min at 56uC, to inactivate complement, were used)
for 6 h, 12 h, 24 h or 36 h at 37uC. The percentage of apoptotic
cells was analyzed by staining with FITC-annexin V (AV) and PI
as described. Sample were run on a cytofluorimeter CyAn ADP
(Dako, Glostrup, Denmark), equipped with an argon ion and
HeNe red laser to excite FITC, PE or APC, respectively, gated on
the basis of side and forward scatter and apoptotic cells were
evaluated as AV
+PI
+ cells.
ELISPOT for cytokine detection and ELISA for
immunoglobulins
BM and PB plasma of patients undergoing imatinib therapy
were analyzed for the content of cytokines able to induce B
lymphocyte growth and/or differentiation, such as interleukin (IL)-
4, IL-6, IL-3, IL-10, IL-21 or BAFF [19–23], for the levels of
BMP2, BMP7 and of the chemokines MCP-1, SDF-1, IP-10 and
IL-8 [23,24], by ELISPOT Multiplex kits (Bioclarma, Turin, Italy)
and referred to standard curves. In some experiments, superna-
tants (SN) from BM cultures obtained from 6 CML patients at
diagnosis and exposed in vitro to 5 mM imatinib mesylate for 3 to
Table 1. Characteristics of CML patients at diagnosis in
chronic phase.
Age
Median (range)
53 (22–73)
Sex
Males/Females
25/15
Sokal risk score
Low
Intermediate
High
14 (36%)
16 (39%)
10 (25%)
Response at 3 mo
CHR/,CHR/noCHR
1
18/14/8
Response at 6 mo
CCgR or PCgR/,PCgR/no CgR
1
28/10/4
Response at 12 mo
CCgR or PCgR/,PCgR/no CgR
1
CMoR/MMoR
1
32/4/4
5/14
1CHR: complete hematologic response (normalization of peripheral blood count
and no palpable spleen); CCgR: complete cytogenetic response (Ph
+ none);
PCgR: partial cytogenetic response (Ph
+ 1–35%); no CgR: no cytogenetical
response (Ph
+.95%); ,:less than; ,PCgR include minor (Ph
+ 36%–66%) and
minimal (Ph
+66–90%); CMoR: complete molecular response (transcript non-
detectable); MMoR: major molecular response (,0.1%). All these definitions of
the clinical response have been assigned according to the European
LeukemiaNet. (Numbers in bold: non responder patients, i.e. no CHR, no CgR at
3 and 6 mo; these patients underwent imatinib 800 mg/daily after 6 mo and
nilotinib or dasatinib after 12 mo).
doi:10.1371/journal.pone.0018925.t001
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Results are expressed as pg/mL.
IgM and IgG content was measured in BM plasma by ELISA,
using a commercial kit (Bethyl Laboratories, Inc., Montgomery,
TX, USA) containing specific antibodies against these Ig classes
and HRP-streptavidin conjugated secondary antibodies. Following
development with ABTS, plates were read at OD405, referred to a
standard curve and results expressed as mg/dL.
mRNA isolation, reverse transcription and Q-RT-PCR for
SDF-1, BAFF, BMP2 and BMP7
Total RNA was extracted with TriPure (Roche Diagnostics,
Milan, Italy) from cells isolated from BM samples, before and after
imatinib treatment, and reverse-transcribed with random primers.
In some experiments, BM specimens of 6 CML patients at
diagnosis were cultured in vitro for 3 to 14 days with 5 mM of the
purified imatinib mesylate (Novartis Pharma AG, Basel, Switzer-
land, MTA31812); cells were recovered at day 3, 5, 7 and 14 for
RNA extraction. Primers for BAFF, SDF-1, BMP2 and BMP7
amplifications and probes were purchased from Applied Biosystem
(userid: Hs00198106_m1, Hs00171022_m1, Hs01055564_m1
and Hs00233477_m1, respectively). Q-RT-PCR was performed
on the 7900HT FastRT-PCR system (Applied Biosystems) with
the fluorescent Taqman method [25]. mRNAs were normalized to
18s as a control gene, and referred to a standard curve, i.e. serial
dilutions of plasmids containing cloned sequences of Abl (Applied
Biosystem). After subtracting the threshold cycle (CT) value for 18s
(Applied Biosystem) from the CT values of the target genes, the
DCT values were converted with the formula 2
-DDCT to show the
fold relative increase in mRNA expression compared to levels
prior to imatinib treatment, which were given the arbitrary value
of 1 [26].
Statistical analysis
Data are presented as mean6SD. Statistical analysis was
performed using ANOVA for repeated measures. Pearson
coefficient (r) at 99% confidence interval was calculated to
correlate the number of CD20
+CD5
+sIgM
+cells with the plasma
concentrations of IgM or SDF-1/BAFF and the levels of
transcription of SDF-1/BAFF with BMP2/BMP7. Correlation
between each of these parameters and clinical response (cytoge-
netical response, CgR, or molecular response, MoR) was
evaluated with the Spearman coefficient (rs) at 95% confidence
interval and by multivariate regression analysis.
Results
CML patients responding to imatinib show high numbers
of BM CD20
+CD5
+sIgM
+ lymphocytes and high
concentrations of BM IgM
Forty CML patients, that underwent imatinib treatment
(400 mg/daily), were studied (Table 1). Among them, 32 were
defined responders (R) as they obtained either optimal response
(n=18), or suboptimal (n=14) response; eight patients were non
responders (NR) as they underwent failure of treatment, or loss of
response at 6 months (n=4), according to the LeukemiaNet
recommendations [18]. Most R patients (n=19) had complete
(CMoR, n=5) or major molecular response (MMoR, n=14) by
12 months (Table 1) and maintained it at 18 months. None of NR
patients showed any of the known mutations responsible for
imatinib resistance (not shown).
BM aspirates were drawn at diagnosis (t0), after 3, 6, 12 and 18
months of imatinib therapy. Cytofluorimetric analysis, performed
at the mentioned time points, showed in R patients an increase of
CD20
+ lymphocytes (range 20–25% of BM lymphocytes vs 8–10%
in the BM of NR patients) mostly coexpressing surface IgM and
CD5 (Figure 1A). At diagnosis the number of CD20
+ cells in all
CML patients (R and NR) was lower than in healthy donors (range
8–12% of BM lymphocytes vs 18–20% in the BM of healthy
donors, not shown), in agreement with other reports [27]. Besides
the recovery of BM B cells, in R patients these CD20
+CD5
+sIgM
+
cells represented about the 15–18% of the BM lymphocytes after
3 mo of imatinib therapy, whereas it was 5% or less in NR patients
(Figure 1A and B). Also, this CD20
+CD5
+sIgM
+ cell population
increased, although to a lesser extent, in the PB of R patients
(Figure S1 A).
BM plasma samples were also evaluated for IgM and IgG
content. As shown in figure 1C, the amount of IgM significantly
increased in the BM of R patients (.350 mg/dL at 3 mo vs
,200 mg/dL at t0; p,0.001), compared to NR (.350 mg/dL at
3m oi nRv s,250 mg/dL at 3 mo in NR, p,0.001) and to the
levels of IgM in the BM plasma from H donors (,250 mg/dL); no
increase of IgG was observed (Figure 1D). The increase in IgM
levels was also detectable and significant (p,0.01), although less
evident, in PB samples (Figure S1 B). A significant correlation
between the number of CD5
+IgM
+ B cells in the BM at mo 3 and
the levels of IgM (r=0.812) content in BM plasma at the same
time point was found.
BM IgM from responder CML patients react with
leukemic cells
Since it has been described that a population of CD5
+ B cells
can produce ‘‘natural’’ antibodies, mainly of IgM isotype,
potentially reactive with solid tumor cells [28,29], we investigated
whether the IgM fraction of BM plasma contain antibodies
reacting with leukemic cells in CML. To this aim, purified CML
cells were incubated with BM plasma from R or NR patients,
followed by FITC-conjugated anti-IgM or anti-IgG antiserum.
Figure 2A shows that IgM reactive with autologous CML were
present at 1:10 dilution in R patients (A, left histogram) and with a
very low reactivity in NR patients (A, central histogram), whereas
no anti-CML IgG antibodies were found (A, right histogram).
Although not shown, no reactivity was observed with mononuclear
cells from healthy donors; moreover, R patients’ plasma samples
were still reactive at 1:80 dilution, at variance with samples from
NR patients (not shown). It has been reported that the largest
proportion of IgM natural antibodies with anti-cancer reactivity is
directed against tumour associated carbohydrate epitopes [29,30];
to address this point, CML cells were pre-treated with either O-
glycosidase or N-glycosidase before incubation with patients’
plasma samples and staining with FITC-conjugated anti-IgM
antibody. Of note, we found that pre-treatment of autologous
(Figure 2B) or allogenic (Figure 2C) CML cells with O-glycosidase,
at variance with N-glycosidase, strongly reduced the reactivity of
patients’ sera. This was mostly evident in R patients (Figure 2C),
probably due to the higher amounts of IgM antibodies in their
plasma.
IgM natural antibodies directed against tumor-associated
carbohydrates have been shown to exert both complement-
dependent cytotoxicity and apoptosis [29–31]. Interestingly, BM
plasma (1:10 diluted) from R patients could induce apoptosis of
CML cells from either R or NR patients (about 25–30%) in 24–
36 h, whereas plasma samples from NR patients or healthy (H)
donors were significantly less effective (,15–20% of apoptosis by
36 h) (Fig. S1, A and B). Superimposable results were obtained
with plasma samples heated at 56uC (not shown), thus making
unlikely a potential complement-depending mechanism.
Anti-Leukemic Antibodies in CML Patients
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e18925Increased SDF-1/BAFF production in the BM of CML
patients responding to imatinib therapy
BM and PB plasma were analyzed, at diagnosis and at 3 mo
after imatinib therapy, for the content of cytokines able to induce
B lymphocyte proliferation and/or differentiation, such as
interleukin (IL)-4, IL-6, IL-3, IL-10, IL-21 or BAFF and for the
levels of chemokines potentially active on B cells such as MCP-1,
IP-10 and IL-8 [7,19–24]. SDF-1 was tested as an additional factor
acting on B cell growth and differentiation [9,10]. Of the different
cyto-chemokines analyzed, SDF-1 was found to be significantly
increased in the plasma of BM (Figure 3A, left panel, .400 pg/
mL at 3 mo vs about 100 pg/mL at t0, p,0.001) and in part also
in the PB (Figure S1 C, .150 pg/mL vs about 25 pg/mL,
p,0.001) 3 mo after the beginning of imatinib therapy. More
importantly, this increment was detectable in R patients, but not in
NR (Figure 3A, p,0.001, and Figure S1 C). A less strong, but
significant increase of BAFF was also detectable in the BM
(Figure 3A, right panel, .200 pg/mL vs. 40 pg/mL, p,0.01) and
PB plasma (Fig. S1 D, .100 pg/mL vs about 20 pg/mL, p,0.01)
of R patients, at variance with NR patients. Likewise, increased
transcription of either SDF-1 (Figure 3B, left panel) or BAFF
(Figure 3B, right panel) was observed in R, at variance with NR,
patients at month 3. No detectable levels of (IL)-4, IL-6, IL-3, IL-
10, IL-21 or IL-8, were found (not shown). Interestingly, statistical
analysis showed a significant correlation between the number of
CD20
+CD5
+ B cells in the BM at mo 3 and the levels of SDF-1
(r=0.761 for mRNA and r=0.798 for protein content in BM
plasma) or BAFF (r=0.721 for mRNA and r=0.782 for protein
content in BM plasma). Of note, multivariate analysis revealed
that BM CD20
+CD5
+ B cells at 3 and 6 mo are linked to the levels
of SDF-1 (p,0.0001) and BAFF (p,0.001).
It has been reported that SDF-1 production can be stimulated
by BMP2 and BMP7 [24]; thus transcripts for these proteins were
analyzed in BM samples of CML patients at diagnosis and 3 mo
after imatinib therapy. As shown in figure 3, transcription of
BMP2 (C) and BMP7 (D) increased significantly only in R patients.
Interestingly, a significant correlation between SDF-1 and BMP2
(r=0.852) or BMP7 (r=0.810) transcription and between BAFF
Figure 1. Increased CD20
+CD5
+sIgM
+ lymphocytes and IgM plasma concentrations in the BM of CML patients upon imatinib
therapy. BM samples were drawn after 3 mo of therapy (A–D) or at the time of diagnosis (t0) (B–D). Panels A and B: cells isolated from BM were
stained with the APC-conjugated anti-CD20, followed by the FITC-conjugated anti-IgM mAb, and/or the PE-conjugated anti-CD5 mAb. Samples were
run on a Cyan ADP cytofluorimeter, gated on lymphocytes and to exclude non viable cells and debris, and results expressed as log far-red
fluorescence intensity (a.u.) (A) vs. log green fluorescence intensity (left dot plots) or log red fluorescence intensity (right dot plots), or percentage of
positive cells (B). Panel A: R (upper dot plots) and NR (lower dot plots) patient specimens at mo 3; numbers in upper left (UL) and upper right (UR)
quadrants indicate CD20
+sIgM
2 (UL) or CD20
+sIgM
+ (UR cells (left dot plots) and CD20
+CD5
2 (UL) or CD20
+CD5
+ (UR) cells (right dot plots). Panel B:
BM CD20
+CD5
+sIgM
+ cells at t0 and mo 3 in R and NR patients. Mean6SD from 32 R and 8 NR patients. * p,0.001 vs NR and t0. Panels C and D: IgM
(C) and IgG (D) content was measured in BM plasma samples from R or NR patients or 10 healthy (H) donors by ELISA using a commercial kit
containing specific antibodies against these Ig classes and HRP-streptavidin conjugated secondary antibodies. Following development with ABTS,
plates were read at OD405, referred to a standard curve and results expressed as mg/dL. Mean6SD from 32 R and 8 NR patients. * p,0.001 vs t0;
** p,0.001 vs NR.
doi:10.1371/journal.pone.0018925.g001
Anti-Leukemic Antibodies in CML Patients
PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18925and BMP2 (r=0.796) or BMP7 (r=0.679) transcription was
found. Again multivariate analysis showed that SDF-1 and BAFF
transcription are related to BMP2 (p,0.0001 and p,0.001
respectively) and BMP7 mRNA levels (p,0.0001 and p,0.001
respectively).
Increased production of SDF-1 and BAFF by CML BM cells
exposed to imatinib in vitro
To further analyze the observed effects of imatinib, BM cells
obtained from 6 CML patients (n=4 R, n=2 NR) at diagnosis (t0)
were cultured in the absence or presence of the imatinib mesylate
(5 mM). Cells and SN were then recovered at different time points
for the quantification of SDF-1 or BAFF mRNA by Q-RT-PCR
and protein amount by ELISA. SDF-1 transcription was
detectable from day 3, with a peak on day 7, and a decrease on
day 14 of exposure to imatinib in cell cultures from R CML
patients (Figure 4A); in turn, BAFF mRNA was transiently
detectable on day 5 (Figure 4B). Significant amounts of SDF-1
protein were evidenced in the SN from R patient cultures
(Figure 4C, n=4) on day 5 (100 pg/mL vs ,10 pg/mL at t0) and
7 (125 pg/mL vs ,10 pg/mL at t0), while BAFF was present in
the same SN in lower amounts on day 5 (Figure 4D, 50 pg/mL vs
Figure 2. BM IgM from responder CML patients react with leukemic cells. Leukemic cells (CML) from R (panels A-C) or NR (panel C) patients
were used. After incubation with BM plasma and staining with FITC anti-human IgM or IgG, samples were run on a CyAn ADP cytofluorimeter, gated
on leukemic cells, after exclusion of cell debris on the basis of FSC and SSC, and results expressed as log green fluorescence intensity (a.u.) vs number
of cells (A and B) or as percentage of positive cells (C). Panel A: Black lines: BM plasma samples of representative R (left and right histograms) or NR
(central histograms) patients, diluted 1:10, were incubated with R CML, followed by FITC-anti-human IgM (left and central histograms) or anti-human
IgG (right histogram) antisera. Numbers in each histogram: percentage and mean fluorescence intensity (arbitrary units, a.u.) of positive cells. Grey-
dotted lines: CML incubated with FITC-anti-human IgM or anti-human IgG antisera alone. Panel B: CML cells from a representative R patient were
untreated (grey-dotted lines) or treated (black lines) with 20 mU/mL O-glycosidase (left histogram) or 10 mU/mL N-glycosidase (central histogram) for
4 h at 37uC before incubation with autologous BM plasma followed by FITC-anti-human IgM antiserum; right histogram: CML incubated with FITC-
anti-human IgM alone. Numbers in each histogram: percentage and mean fluorescence intensity (a.u.) of positive cells. Panel C: CML cells from R
(black columns) or NR (white columns) patients, untreated (2) or treated (+) with O-glycosidase were incubated with BM plasma samples from R or
NR patients, followed by FITC-anti-human IgM, run on a CyAn ADP as above, and results expressed as percentage of positive cells. Mean6SD from 22
R and 8 NR patients. * p,0.001 vs NR; **p,0.001 vs (2).
doi:10.1371/journal.pone.0018925.g002
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proteins were detected in BM cell cultures from the two NR
patients (Figure 4C and D). Moreover, no variations in BMP2 or
BMP7 transcripts were observed in BM cells upon in vitro exposure
to imatinib (not shown), suggesting that the whole BM microen-
vironment is required for imatinib to exert its complete effect.
BM CD20
+CD5
+sIgM
+ lymphocytes, plasma levels of
IgM and SDF-1/BAFF production upon imatinib thera-
py: an 18months follow up. BM aspirates were drawn at
diagnosis and after 3 mo; then, follow up was carried out with BM
aspirates at 6 mo and every 6 months: figure 5 depicts the results
at 3, 6, 12 and 18 months. The significant high number of BM
CD20
+CD5
+sIgM
+ lymphocytes in R patients, early after imatinib
treatment (3 mo), was observed also after 6 months (18% in R
patients vs 4% in NR patients, p,0.001) and still detectable (6–
8%), although decreased, after one year (Figure 5A). Also the
amount of IgM remained significantly increased in the BM of R
patients, up to 6 months after the beginning of imatinib therapy
(Figure 5B, .400 pg/mL in R patients vs ,200 pg/mL in NR
patients). Along this line, high levels of SDF-1 transcription
(Figure 5C) and secretion (Figure 5D), and to a lesser extent of
BAFF (not shown), were detectable in the BM of R patients up to 6
months. Conversely, in NR patients, no increase of each
parameter was observed during therapy (Figure 5). Statistical
analysis revealed a significant correlation between clinical response
to imatinib therapy (CgR at 6 mo and MoR at 12 mo), number of
BM CD20
+CD5
+sIgM
+ lymphocytes (rs=0.680 vs CgR,
rs=0.0571 vs MoR), BM IgM plasma concentration (rs=0.640
vs CgR, rs=0.478 vs MoR) and SDF-1 levels (rs=0.658 vs CgR,
rs=0.547 vs MoR) in BM plasma. All R patients showing CCgR
and CMoR/MMoR at 12 months (Table 1), maintained this
cytogenetic/molecular pattern and clinical remission at 18 months
(not shown). Of note, multivariate analysis revealed that BM
CD20
+CD5
+sIgM
+ lymphocytes, BAFF/SDF1 and IgM BM
plasma concentrations at 3 mo might be considered as predictive
of CCR (p,0.0001) or MMoR (p,0.01) at 12 mo.
Discussion
Imatinibmesylateisapproved totreatnewlydiagnosedPh
+CML
in chronic phase and recent 6- and 7-years updates of the phase 3
International Randomized Study of Interferon and STI571 (IRIS)
trial have confirmed both long-term efficacy and safety of the
treatment, with an estimated overall survival rate of 86% [2,11]. In
another type of imatinib-sensitive tumor, a rare form of gastroin-
testinal stromal cancer, the response to the drug is also linked to the
activation of the immune system with production of antineoplastic
cytokines [3–5], thus raising the possibility that this mechanism
might contribute to a good pharmacological response. Additional
evidence for immune response amplification mediated by imatinib
have been reported, including the enhancement of antigen
presentation by dendritic cells from CML patients [32].
Herein we show that, in patients responding (R) to imatinib
treatment, clinical and cytogenetic response is paralleled or
preceded by early cytologic, phenotypic and molecular changes in
theBM,involvingtheB cell compartment,that arenot detectablein
Figure 3. SDF-1, BAFF, BMP2 and BMP7 production in the BM of CML patients following imatinib therapy. BM samples were drawn at
diagnosis (t0) or 3 months (3mo) after therapy with imatinib. Panel A: SDF-1 (left histograms) or BAFF (right histograms) content was measured in BM
plasma by ELISA, referred to a standard curve and results expressed as pg/mL. Mean6SD from 32 R and 8 NR patients. * p,0.001 vs t0; **p,0.001 vs
NR. Panels B–D: total RNA was extracted from cells isolated from BM samples before (t0) and after (3 mo) imatinib treatment and reverse-transcribed
with random primers. Q-RT-PCR was performed with primers and probes for SDF-1 (B, left histograms), BAFF (B, right histograms), BMP2 (C) and BMP7
(D) on the 7900HT FastRT-PCR system with the fluorescent Taqman method. mRNAs were normalized to 18 s as a control gene, and referred to a
standard curve. Results are expressed as the fold relative increase in mRNA expression compared to the control gene. Mean6SD from 32 R and 8 NR
patients. * p,0.001 vs t0; **p,0.001 vs NR.
doi:10.1371/journal.pone.0018925.g003
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decreased in CML patients, upon imatinib therapy has been
previously described [27]. We confirmed these findings and provide
evidence that among B lymphocytes a subset is increased in R, but
not in NR patients. In particular, a raise in the CD20
+CD5
+sIgM
+
cell population is evidenced as early as 3 mo after the beginning of
therapy and persists up to 6–9 mo. This population of cells is
conceivably antibody-secreting, as an increase of IgM is also
measured in the BM plasma of R patients. It is of note that this IgM
fractioncontainsantibodiesreactive with O-linked olygosaccharides
expressed by leukemic cells and are capable to kill them by a
complement-independent mechanism. Such antibodies resemble
the so called ‘‘natural antibodies’’, that are indeed produced by
CD5
+ B lymphocytes and in healthy donors are mainly IgM
involvedincomplement-dependentanti-bacterialresponses;natural
IgM antibodies recognizing sugars, including O-linked olygosac-
charides, have been reported also in patients with solid tumors,
where they contribute to clear tumor cells by apoptosis [28–31]. A
reduced concentration of gammaglobulins has been reported in the
sera of a fraction of patients (one fourth) receiving imatinib
treatment [33]; however, in that case, imatinib was administered at
higher doses (up to 600 mg/daily) than in our study and only
peripheral blood serum was considered. In the BM of CML
patients, cell types other than lymphocytes or leukemic cells are
present, including stromal cells.
In the BM of R patients, SDF-1 and, to a lesser extent, BAFF
production is induced by imatinib both in vitro and in vivo,a t
variance with NR patients; both SDF-1 and BAFF have been
reported to contribute to normal B cell development and
maturation [9]. Thus, imatinib seems to be capable of modulating
the BM microenvironment leading to conditions favourable to B
cell differentiation. The reported observation that dasatinib,
another tyrosine kinase inhibitor, does not restore the total B cell
population in the BM of treated patients [27], might be due to the
different effect of the two drugs, imatinib and dasatinib, mainly on
stromal cell compartment. Indeed, dasatinib inhibits a broader
range of kinases compared to imatinib [27]. It is tempting to
speculate that imatinib treatment is able to ‘‘reset’’ the BM
microenvironment, involving stromal cells possibly responsible for
SDF-1 and BAFF production, that, in turn, would enhance the B
cell compartment. This might be due to the therapeutic effects
exerted by imatinib on the myeloid malignant progenitors [34,35],
that would be substituted by normal progenitors, capable of
repopulating the BM with normal stromal as well as normal
myeloid cells. In our in vitro experiments, a number of cells
expressing the CD105 stromal cell marker [36] grew in cultures of
BM from R patients in the presence of imatinib, at variance with
NR (not shown). This hypothesis seems to be also supported by
our finding that in the BM of R patients, BMP2 and BMP7
transcription are increased. Effects of imatinib on the osteoblas-
togenesis and bone marrow remodelling, mediated by BMP2, have
been recently reported [37]. Of note, SDF-1 synthesis has been
related to both BMP2 and BMP7 [24]; moreover, BAFF synthesis
and release by normal myeloid cells has been described [38].
Figure 4. SDF-1 and BAFF production in the BM of CML patients following in vitro exposure to imatinib. Cells isolated from BM samples
of 6 CML patients (4R and 2NR) at diagnosis (t0) were cultured in vitro for 3 to 14 days without (medium) or with 5 mM purified imatinib mesylate;
cells were recovered at day 3, 5, 7 and 14. Total RNA was extracted and reverse-transcribed. Q-RT-PCR was performed with primers and probes for
SDF-1 (panel A) or BAFF (panel B) on the 7900HT FastRT-PCR system with the fluorescent Taqman method. mRNAs were normalized to 18 s as a
control gene, and referred to a standard curve. Results are expressed as the fold relative increase in mRNA expression compared to levels prior to
imatinib in vitro treatment. Mean6SD from 4 R and 2 NR patients. * p,0.001 vs 3d; **p,0.001 vs NR. Panels C and D: SDF-1 (C) and BAFF (D) content
was measured in SN of BM cells of CML patients (R, n=4; NR, n=2), at t0 or cultured as above and recovered on day 5 and 7, by ELISA kit, referred to
standard curve and results expressed as pg/mL. Mean6SD from 4 R and 2 NR patients. * p,0.001 vs 3d; **p,0.001 vs NR.
doi:10.1371/journal.pone.0018925.g004
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PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e18925Recently, a CML-protective effect exerted by SDF-1 agonists on
leukemic cells in blastic phase, has been reported [39]. However,
there is no direct evidence, so far, for a role of this cytokine on
CML cells in chronic phase and their progenitors; rather, SDF-1
has been shown to block colony forming units by both healthy and
CML CD34
+ cells [40]. It remains to be defined the contribution
given in vivo by the CD20
+CD5
+ IgM-secreting B cells population
observed in R patients to the clearance of leukemic cells. In any
case they would represent the enhancement of B cell maturation
and function in a restored BM, as an early sign of the response to
the treatment; indeed, both the number of these cells and the levels
of IgM antibodies are statistically related to the pharmacological
response.
In conclusion, the BM of R patients would benefit by the renewal
of the whole microenvironment, due to the efficacy of imatinib
mesylate treatment, documented by BMP, BAFF and SDF-1
production, and leading to the development of the observed B cell
population producing tumor-reactive IgM. These changes are
transiently detectable for a period of up to 6–9 months, by which
time the resetting process would be concluded, as proved by the
stability of the clinical, cytogenetic and molecular response. A
statistically significant correlation to the clinical, cytogenetical and
molecularresponseinR patientswasfound;providedthesedata will
be confirmed in a larger cohort of patients, we propose that they
may contribute to the early identification of NR patients, and help
in the choice of alternative therapeutic strategies.
Supporting Information
Figure S1 CD20
+CD5
+sIgM
+ lymphocytes and IgM,
SDF-1, BAFF content in the PB of CML patients upon
imatinib therapy. PB samples were drawn at diagnosis (t0) or 3
months after imatinib. Panel A: cells isolated from PB were stained
with the APC-conjugated anti-CD20, followed by FITC-conjugated
anti-sIgM and by the PE-conjugated anti-CD5 mAb. Samples were
run on a CyAn ADP cytofluorimeter, gated on lymphocytes and to
exclude non viable cells and debris, and results expressed as
percentage of positive cells. Mean6SD from 32 R and 8 NR
patients. * p,0.01vst0;**p,0.001 vsNR.Panel B: IgM content was
measured in PB plasma samples from R or NR patients and healthy
(H) donors by ELISA using a commercial kit containing specific
antibodies against these Ig classes and HRP-streptavidin conjugated
secondary antibodies. Following development with ABTS, plates
were read at OD405, referred to a standard curve and results
expressed as mg/dL. Mean6SD from 32 R and 8 NR patients.
*p ,0.01 vs t0; **p,0.001 vs NR. Panels C and D: SDF-1 (C) or
BAFF (D) content was measured in PB plasma by ELISA, referred to
a standard curve and results expressed as pg/mL. Mean6SD from
32 R and 8 NR patients. * p,0.01 vs t0; **p,0.001 vs NR.
(TIF)
Figure S2 Apoptosis of CML cells upon incubation with
BM plasma: comparison among R and NR patients.
CML cells, obtained from R (panel A) or from NR patients (panel
B) as described, were incubated with BM plasma from R or NR
patients or healthy donors (H) for 6 h, 12 h, 24 h or 36 h at 37uC.
The percentage of apoptotic cells was analyzed by staining with
FITC-annexin V and PI as described. Sample were run on a
CyAn ADP, gated on the basis of side and forward scatter and
results expressed as percentage apoptotic cells evaluated as
AV
+PI
+ cells. Mean6SD from 22 R and 8 NR patients and from
8 H donors. * p,0.001 vs medium and H plasma; **p,0.001 vs
NR.
(TIF)
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